Clinical Trial

Bupivacaine for Postoperative Pain After Laparoscopic Hysterectomy

Study acronym: bupivacaine
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 27, 2026 (before its estimated June 4, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective, randomized, single-blind controlled study aims to evaluate the effect of bupivacaine injection at trocar entry sites and the vaginal cuff on postoperative pain in patients undergoing total laparoscopic hysterectomy for benign gynecologic conditions. Postoperative pain after laparoscopic hysterectomy may arise from trocar insertion sites and surgical manipulation of the vaginal cuff. Local anesthetic infiltration may reduce somatic pain and improve early recovery. Eligible patients will be randomly assigned to either receive 0.5% bupivacaine injection at trocar sites and the vaginal cuff at the end of surgery or receive no local anesthetic injection (control group). All patients will receive standard postoperative analgesia. Postoperative pain will be assessed using the Visual Analog Scale (VAS) at 1, 2, 3, 6, 12, and 24 hours after surgery. Secondary outcomes include additional analgesic requirement, time to first mobilization, time to first flatus, length of hospital stay, and postoperative complications.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-02-21; most recent amendment 2026-05-22.
Trial Details
NCT Number NCT07435909
Lead Sponsor Serkan Kumbasar
Conditions Postoperative Pain
Enrollment 120 participants
Start Date 2025-08-28
Primary Completion 2026-06-04 (estimated)
Study Completion 2026-06-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-27